The total number of people suffering from FA has not been documented worldwide.Scientists estimate that the carrier frequency (people carrying a defect in one copy of a particular FA gene, while the other copy of that same FA gene is normal) for FA in the United States of America is 1 in 181. The incidence rate, or the chance of an offspring being born with FA, is about 1 in 131,000 in the U.S., with approximately 31 children born with FA each year. (Schroederet al., 1976; Swift et al.,1971). Fanconi anemia has been reported inall ethnic groups. However, due to founder effects, the heterozygote frequency is greater in South African Afrikaners, (Rosendorff et al.,1987) sub-Saharan blacks (Neil et al., 2005), and Spanish gypsies (Callen et al., 2005) than in the general world population. The expected birthrates in these ethnic groups are around 1 case per 40,000 births. The carrier frequency is about 1 case per 90 people for the Ashkenazi Jews in the United States(Rosenberg 2011). The male-to-female ratio is 1.2:1,though equal numbers are predicted in a disorder with over 99% autosomal recessive inheritance. Fanconi anemia has been diagnosed in patients from birth to 49 years, with a median age of 7 years. Individuals with birth defects are diagnosed at younger ages when compared to those without any birth defects (Tanguichi etal., 2006).
ETIOLOGY/BIOLOGY OF FANCONI ANEMIA:
Sixteen FA complementation groups have been characterized so far (A, B, C, D1/BRCA2, D2, E, F, G, I, J/BACH1/BRIP1, L, M, N/PALB2, O/RAD51C, FANCP/SLX4 and FANCQ/ERCC4) (Crossanet al., 2012, Boglilo et al., 2013). All FA genes except FANCB are located on autosomes. FANCB is located on the X chromosome (Meetei et al., 2004). Table 1 depicts the chromosomal location of the 16 FANC genes. Individualswith mutations in any of these 16 FA genes share a distinctiveclinical and cellular phenotype, and these 16 gene products function in a common cellular pathway, called the Fanconi anemia pathway (Kee et al., 2010).
The basic FA pathway
DNA is replicated by DNA polymerase from multiple replication forks. Any lesions that disturb the structure of the chromatin, such as chemically induced DNA crosslinks, result in stalling of replication at the position of the lesion. The Fanconi Anemia pathway mainly acts in response to DNA damage that leads to the stalling of the DNA replication forks during S phase of the cell cycle. The activation of the FA core complex, that consists of at least 8 of the known FA proteins (A, B, C, E, F, G, L, and M) occurs through the recruitment of ATR (ataxia telangiectasia and Rad3 related) (Andreassen et al., 2004) to the single-stranded DNA at stalled replication fork (Zou and Elledge 2003). The activated FA core complex functions as an E3 ubiquitin ligase that mono-ubiquitinates FANCD2 (Fanconi anemia complementation group D2). FANCL is the putative catalytic element of the core complex complex. FANCL consists of a PHD domain and bears homology to other known E3 ubiquitin ligases (Meetei et al., 2003a). The monoubiquitination of FANCD2 results in its relocalization from the soluble nuclear compartment to the chromatin (Wang et al., 2004) and subsequently in its association with other repair proteins, such as BRCA1, RAD51, NBS1, and PCNA and with FANCD1/breast cancer 2, and early onset (FANCD1/BRCA2) in the chromatin (Wang et al., 2004; Garcia-Higuera et al., 2001; Tanguichi et al., 2002; Nakanishi et al., 2002; Hussain et al., 2004). During S phase of the normal cell cycle, the core complex, monoubiquitinates FANCD2 on Lys 561 and an induced monoubiquitination occurs when cells are exposed to DNA damaging substances such as MMC, IR and UV radiations (Garcia-Higuera et al., 2001; Gregory et al., 2003). Along with FANCD2, complex 1 also results in the monoubiquitination of FANCD1 (REF). DONE
Cells that cannot to form complex 1 or complex 2 are generally hypersensitive to cross-linking agentssuch as MMC and these cells exhibit the characteristic broken and radial chromosome forms of FA. Mutations in eight FA subtypes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM) result in loss of FANCD2 and FANCI monoubiquitylation, which is the central regulatory step in the FA pathway. 90% of individuals with FA are reported to have mutations recorded in these eight FA genes (Table 1).
A close association has been established between the FA pathway and the BRCA proteins in the DNA repair mechanisms. BRCA2 was identified as an FA gene – FANCD1 (ref 27 ). FANCN/PALB2 is a known partner of BRCA2/FANCD1 and aids in its localization. (refs. 29, 30), FANCJ/BRIP1 (BRCA1-interacting helicase1) (refs. 31, 32), and, FANCO (RAD51C; an already known homologousrepair factor; refs. 33, 34) further strengthen the intricate associationof breast and ovarian susceptibility genes with FA.
There is clinical variability among FA patients, owing to the different FA subtypes.(1). FA patients of subtype A have milder disease and late onset of bone marrow failure. Patients of subtypes FANCC and FANCG generally have a more severe phenotype and require early intervention that includes bone marrow transplantation. While FA patients assigned to subtype FANCI have early onset and increased incidence of solid tumors and leukemia (35). In general, diagnosing the disease at an early stage and identifying the gene mutated is important for genetic counseling of parents with FA patients with regard to future pregnancies.
CLINICAL FEATURES/ PATHOPHYSIOLOGY OF FA
Individuals with FA exhibit numerous congenital defects, butapproximately 25%–40% of FA patients are physically normal (D’Andrea 2010)). Majority of children with FA have congenital skeletal anomalies of the thumb and forearm. The thumbs are usually smaller (hypoplastic), duplicated, or absent and the forearm radius is either reduced or absent (Giampietro et a., 1993). Fig represents the commonly observed deformities seen in FA patients. Several FA patients display endocrine abnormalities. More than half of FA individuals have short stature which has been attributed to insufficient growth hormone production and hyperthyroidism. There are also reports of FA patients with normal stature and no obviousdeficiency in growth hormone production. Abnormal glucose or insulin metabolism has also been associated with FA. While individuals with diabetes have reduced insulin levels, FA individuals generallyhave a higher level of serum insulin. Reports suggest that approximately 8% ofindividuals with FA are diabetic, while up to 72%have elevated serum insulin levels (Giri et al., 2007; Elder et al., 2008). In addition, osteoporosis has also been associatedwith FA (Wajnrajch et al., 2001; Rietscheli et al., 2001). Hematological abnormalities are the most predominant pathological manifestation of FA. 75%–90% of FA patientsdevelop bone marrow failure, aroundthe first decade of life (Butturini et al., 1994; Kutler et al., 2003).
In addition to bone marrow failure, most FA patientsdevelop varying degrees of blood disease, these include aplastic anemia,myelodysplastic syndrome (MDS), or acute myeloid leukemia(AML). The risk of AML occurrence in FA patients is approximately 800-foldhigher than that of the general population, with a median age ofonset of 14 years. Recent studies have revealed a common pattern ofchromosomal abnormalities in FA patients with MDSor AML (e.g., gain of 1q23-32, 3q26), suggesings that theseabnormalities can be worthwhile predictive markers (Soulier 2011; Quentin et al., 2011; Meyer et al., 2011; Meyer et al., 2007). The exact cause of these hematopoietic defects is uncertain, althoughincreasing evidence suggests an underlying hypersensitivity of FAhematopoietic cells to oxidative stress (Du et al., 2008).
Although FA is chiefly a pediatric disease, adult FA patientswho are older than 18 years, represent an increasing proportion of the entireFA patient population. This has been attributed to improved management of youngFA patients and a rigorous diagnostic testing in adults. One of themajor health threats faced by adult FA patients is the risk ofacquiring cancer (Taniguchi et al., 2006). In addition to hematologic cancers, solid tumors,predominantly squamous cell cancers (SCCs) of the head and neckand cervical/gynecological cancers, occur at evidently higherrates in FA patients (Kutler et al., 2003). Approximately one-third of FA patientsare reported to develop a solid tumor by their fourth decade of life (Rosenberg et al., 2003). In addition to the hematological abnormalities and increased cancer predisposition, FA individuals also exhibit other clinical problems,which includes hearing loss, ear anomalies as well as reduced fertility (Giampietro et al., 1993). Lowered sperm count is reported in male FApatients, and premature menopause is reported in female patients (Alter et al., 1991). The rate of successful pregnancy is approximately15% among non-transplanted FA patients (Alter et al., 1991), although improved fertility and successful pregnancy has been reported after HSC transplantation (Nabhan et al., 2010). Consistent with reports in FA patients, knock out mouse models of Fanca, Fancc, Fancg, and Fancd2 also exhibited pronounced hypogonadismand impaired fertility, with female offsprings more severely affected than males (Parmar et al., 2009; Koomen et al., 2002).
Effect of Dithiotheritol Dtt Concentration
Immunoglobulin M is the first antibody produced in an immune response and is a pentameric structure held together by sulphide bonds in the J-chain. Dithiothreitol (DTT) cleaves inter-chain and intra-chain sulphide bonds at different concentrations abolishing the haemagglutination property of IgM. Varying concentrations of DTT were examined and it was concluded that concentrations of DTT higher than 0.006 mol/L, completely denatured the structure of IgM leading to loss of agglutination activity.
INTRODUCTION In collaboration with factors of the innate immunity, natural Immunoglobulin M (IgM) provides a first line of defense against invading antigens. IgM is pentameric and is found in serum. In addition to its natural presence, IgM could potentially bind to 10 antigenic determinants per molecule which also enables it to react with a broad spectrum of antigens simultaneously (Boes et al., 1998). The five identical monomers of IgM are made up of two heavy and two light chains that are held together by inter-chain sulphide bonds. The inter-subunit J-chain sulphide bonds hold the four-chain units together forming the larger IgM pentamer (Delves et al., 2011). J-chain is a 15-kDa glycoprotein that is covalently associated by disulfide bonds with IgM (Koshland, 1985).
The reactions of antibody with a multivalent antigen results in the cross linking of the various antigen particles by the antibodies. This eventually results in the clumping of antigen particles by antibodies and is known as agglutination (Coico and Sunshine, 2009). The voluminous IgM antibodies (molecular weight of 970 kDa) have large Fab areas that are far enough apart and thereby facilitate the bridging of red blood cells separated by the zeta potential. This property, and the pentavalence of IgM antibodies is the major cause for the effectiveness of IgM antibodies in interacting with the blood type antigens (RhD) on the surface of erythrocytes resulting in agglutination (Coico and Sunshine, 2009).
Reducing agents such as Dithiothreitol (DTT) inactivates IgM antibody and abolishes agglutination activity (Okuno and Kondelis, 1978). This study was aimed at evaluating and understanding the concentration dependent activity of DTT in the inactivation of IgM.
MATERIALS AND METHODS Sample Preparation: A stock solution of 0.01 mol/L dithiothreitol (DTT) was appropriately diluted with saline (0.9%), in ten fresh sterile tubes, resulting in dilutions ranging from 0.01mol/L to 0.001mol/L. One drop of each of the aforementioned dilution and one drop of diluted anti-D IgM were mixed in further ten tubes. Saline was used as control.
The reaction tubes were incubated in a 37°C water bath for 20 minutes.
Two drops of RhD positive Red Blood Cells (RBCs) were added to each tube, gently mixed and incubated at 20°C (room temperature) for 20 minutes.
Observation of agglutination: The reaction tubes were centrifuged at 800g for one minute and were gently shook over a white background and examined for agglutination.
Addition of second antibody: Two drops of anti-IgM antibody were added to tubes that contained non-agglutinated samples, and were incubated in a water bath at 37°C for 20 minutes.
The samples were then centrifuged at 800g for one minute and were examined for agglutination against a white background.
RESULTS Variations in the concentrations of DTT showed varied levels of agglutination (Table 1). Tubes bearing DTT of concentrations between 0.001 mol/L and 0.006 mol/L and the control tube, showed agglutination. Still, the degree of agglutination observed was much lesser in higher concentrations (0.006 mol/L) compared to lower concentrations (0.001 mol/L). No agglutination was observed at DTT concentrations higher than 0.006 mol/L. No additional change was observed despite addition of anti-IgM antibody to tubes with DTT at concentrations ranging from 0.007 mol/L to 0.01 mol/L, as shown in Table 2.
DISCUSSION Inactivation or fragmentation of IgM can be achieved by treatment with reducing agents such as, 2-mercaptoethanol (2-ME) (Pirofsky and Rosner, 1974), reductant Tris(2-carboxyethyl) phosphine (TCEP) (Getz et al, 1999), or even enzymes such as pepsin (Kishimoto et al., 1968). Obnoxious odour, requirement for dialysis, cost and time factors are certain drawbacks associated with such methods (Getz et al, 1999) Thus treatment with DTT (Okuno